Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics

Friday, April 12, 2019

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new collaboration with Pandion Therapeutics, to apply its antibody optimization platform to the targeting arm of a bispecific antibody. Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease.

"Twist Bioscience, through its Biopharma division, has a highly differentiated capability to optimize antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability and processability,” said Anthony Coyle, Ph.D., co-founder and CEO of Pandion. “We look forward to this initial project on a key therapeutic target that may offer hope for patients in need of new treatment options.”

“By approaching autoimmune and inflammatory disease through antibody therapeutics acting locally at the disease site, Pandion is working to change the trajectory of treatment,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Using our state-of-the-art antibody optimization platform, we look forward to partnering with Pandion to provide enhanced antibodies ideally suited to the human body to potentially improve patient outcomes.”

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024